Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Clin Pharmacol Ther. 2011 Mar;89(3):464-7. doi: 10.1038/clpt.2010.279. Epub 2011 Jan 26.
The slow rate at which pharmacogenetic tests are being adopted in clinical practice is partly due to the lack of specific guidelines on how to adjust medications on the basis of the genetic test results. One of the goals of the Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health’s Pharmacogenomics Research Network (http://www.pgrn.org) and the Pharmacogenomics Knowledge Base (PharmGKB, http://www.pharmgkb.org) is to provide peer-reviewed, updated, evidence-based, freely accessible guidelines for gene/drug pairs. These guidelines will facilitate the translation of pharmacogenomic knowledge from bench to bedside.
药物遗传学检测在临床实践中的采用速度缓慢，部分原因是缺乏关于如何根据基因检测结果调整药物的具体指南。美国国立卫生研究院药物基因组学研究网络（http://www.pgrn.org）的临床药物遗传学实施联盟（CPIC）和药物基因组学知识库（PharmGKB，http://www.pharmgkb.org）的目标之一是提供经过同行评审、更新、基于证据、免费获取的基因/药物组合指南。这些指南将促进药物基因组学知识从实验室到临床的转化。
